OOIR: Observatory of International Research

Papers

(The TQCC of Movement Disorders is 10. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy	316
Type 2 Diabetes as a Determinant of Parkinson's Disease Risk and Progression	125
Rapid Onset Functional Tic‐Like Behaviors in Young Females During the COVID‐19 Pandemic	95
Guidelines for Speech Recording and Acoustic Analyses in Dysarthrias of Movement Disorders	94
Neuroimaging of Anxiety in Parkinson's Disease: A Systematic Review	89
Genotype–Phenotype Relations for Isolated Dystonia Genes: MDSGene Systematic Review	87
Neurofilament Light Chain as a Biomarker for Cognitive Decline in Parkinson Disease	86
GP2: The Global Parkinson's Genetics Program	84
Genetic and Environmental Factors in Parkinson's Disease Converge on Immune Function and Inflammation	81
European Academy of Neurology/Movement Disorder Society‐European Section Guideline on the Treatment of Parkinson's Disease: I. Invasive Therapies	78
Validation of α‐Synuclein in L1CAM‐Immunocaptured Exosomes as a Biomarker for the Stratification of Parkinsonian Syndromes	77
Levodopa Dose Equivalency in Parkinson's Disease: Updated Systematic Review and Proposals	73
Prevalence and Incidence of Huntington's Disease: An Updated Systematic Review and Meta‐Analysis	72
The Role of Cholesterol in α‐Synuclein and Lewy Body Pathology in GBA1 Parkinson's Disease	70
Accelerating Medicines Partnership: Parkinson's Disease. Genetic Resource	67
RT‐QuIC Detection of Pathological α‐Synuclein in Skin Punches of Patients with Lewy Body Disease	67
International Multicenter Analysis of Brain Structure Across Clinical Stages of Parkinson's Disease	66
A Novel SNCA A30G Mutation Causes Familial Parkinsonʼs Disease	66
Bilateral Focused Ultrasound Thalamotomy for Essential Tremor (BEST‐FUS Phase 2 Trial)	65
Systematic Assessment of 10 Biomarker Candidates Focusing on α‐Synuclein‐Related Disorders	64
α‐Synuclein in Plasma‐Derived Extracellular Vesicles Is a Potential Biomarker of Parkinson's Disease	64
Bacterial Butyrate in Parkinson's Disease Is Linked to Epigenetic Changes and Depressive Symptoms	62
The Rostock International Parkinson's Disease (ROPAD) Study: Protocol and Initial Findings	62
GBA and APOE Impact Cognitive Decline in Parkinson's Disease: A 10‐Year Population‐Based Study	61
Prevalence of Parkinson's Disease: A Community‐Based Study in China	60

Closed‐Loop Deep Brain Stimulation for Essential Tremor Based on Thalamic Local Field Potentials	60
Pandemic Tic‐like Behaviors Following Social Media Consumption	59
Global and Regional Changes in Perivascular Space in Idiopathic and Familial Parkinson's Disease	58
Nomenclature of Genetic Movement Disorders: Recommendations of the International Parkinson and Movement Disorder Society Task Force – An Update	58
Longitudinal Changes in Neuromelanin MRI Signal in Parkinson's Disease: A Progression Marker	58
Parkinson's Disease and Post–COVID‐19 Syndrome: The Parkinson's Long‐COVID Spectrum	56
MIND and Mediterranean Diets Associated with Later Onset of Parkinson's Disease	55
Cortical [¹⁸F]PI‐2620 Binding Differentiates Corticobasal Syndrome Subtypes	55
Brain Microglial Activation Increased in Glucocerebrosidase (GBA) Mutation Carriers without Parkinson's disease	53
Clinical Utility of ¹⁸F‐APN‐1607 Tau PET Imaging in Patients with Progressive Supranuclear Palsy	50
Cholinergic Denervation Patterns Across Cognitive Domains in Parkinson's Disease	50
Reduced Synaptic Density in Patients with Lewy Body Dementia: An [¹¹C]UCB‐J PET Imaging Study	49
Efficacy of Omaveloxolone in Friedreich's Ataxia: Delayed‐Start Analysis of the MOXIe Extension	49
Detecting Sensitive Mobility Features for Parkinson's Disease Stages Via Machine Learning	48
Risk of Hospitalization and Death for COVID‐19 in People with Parkinson's Disease or Parkinsonism	48
Diagnostic Value of Salivary Real‐Time Quaking‐Induced Conversion in Parkinson's Disease and Multiple System Atrophy	48
Air Pollution and the Risk of Parkinson's Disease: A Review	47
Dopamine Receptors in Parkinson's Disease: A Meta‐Analysis of Imaging Studies	47
The Mutation Matters: CSF Profiles of GCase, Sphingolipids, α‐Synuclein in PD_GBA	47
Development and Validation of a Patient‐Reported Outcome Measure of Ataxia	46
Cognitive Determinants of Dysarthria in Parkinson's Disease: An Automated Machine Learning Approach	46
Genotype–Phenotype Relations in Primary Familial Brain Calcification: Systematic MDSGene Review	45
Unmet Needs of Women Living with Parkinson's Disease: Gaps and Controversies	45
Parkinson's Disease Phenotypes in Patient Neuronal Cultures and Brain Organoids Improved by 2‐Hydroxypropyl‐β‐Cyclodextrin Treatment	45
How Does Deep Brain Stimulation Change the Course of Parkinson's Disease?	44
Peripheral Immune Profile and Neutrophil‐to‐Lymphocyte Ratio in Parkinson's Disease	44
Serotonergic and Dopaminergic Lesions Underlying Parkinsonian Neuropsychiatric Signs	44
Gait Variability in Spinocerebellar Ataxia Assessed Using Wearable Inertial Sensors	42
Alpha and Beta Synucleins: From Pathophysiology to Clinical Application as Biomarkers	42
The Impact of Type 2 Diabetes in Parkinson's Disease	42
Action Observation and Motor Imagery Improve Dual Task in Parkinson's Disease: A Clinical/fMRI Study	41
Adaptive Deep Brain Stimulation: From Experimental Evidence Toward Practical Implementation	41
In Vivo Assessment of Neuroinflammation in 4‐Repeat Tauopathies	41
Regional Brain and Spinal Cord Volume Loss in Spinocerebellar Ataxia Type 3	41
Differentially Expressed Circular RNAs in Peripheral Blood Mononuclear Cells of Patients with Parkinson's Disease	41
Soluble CD163 Changes Indicate Monocyte Association With Cognitive Deficits in Parkinson's Disease	41
Cannabidiol for Rapid Eye Movement Sleep Behavior Disorder	41
Expiratory Muscle Strength Training for Therapy of Pharyngeal Dysphagia in Parkinson's Disease	40
The Neurophysiology of Sleep in Parkinson's Disease	40
Plasma Phospho‐Tau Identifies Alzheimer's Co‐Pathology in Patients with Lewy Body Disease	40
Parkin Deficiency Impairs Mitochondrial DNA Dynamics and Propagates Inflammation	39
Impact of Obstructive Sleep Apnea on Cognitive and Motor Functions in Parkinson's Disease	39
α‐Synuclein Spread from Olfactory Bulb Causes Hyposmia, Anxiety, and Memory Loss in BAC‐SNCA Mice	39
Development of SARA^home, a New Video‐Based Tool for the Assessment of Ataxia at Home	39
Altered Cholinergic Innervation in De Novo Parkinson's Disease with and Without Cognitive Impairment	38
Modernizing Daily Function Assessment in Parkinson's Disease Using Capacity, Perception, and Performance Measures	38
Parkinson's Disease Is Associated with Impaired Gut–Blood Barrier for Short‐Chain Fatty Acids	37
Mitochondrial and Clearance Impairment in p.D620N VPS35 Patient‐Derived Neurons	37
Accurate Detection of α‐Synuclein Seeds in Cerebrospinal Fluid from Isolated Rapid Eye Movement Sleep Behavior Disorder and Patients with Parkinson's Disease in the DeNovo Parkinson (DeNoPa	36
Immunohistochemical Detection of Synuclein Pathology in Skin in Idiopathic Rapid Eye Movement Sleep Behavior Disorder and Parkinsonism	36

Striatal Blood–Brain Barrier Opening in Parkinson's Disease Dementia: A Pilot Exploratory Study	36
Dissecting the Phenotype and Genotype of PLA2G6‐Related Parkinsonism	36
Clinical Profiles and Mortality of COVID‐19 Inpatients with Parkinson's Disease in Germany	36
Covid‐19 Infection and Parkinsonism: Is There a Link?	36
Abstracts	35
Voice Analysis with Machine Learning: One Step Closer to an Objective Diagnosis of Essential Tremor	35
Salivary α‐Synuclein RT‐QuIC Correlates with Disease Severity in de novo Parkinson's Disease	35
Long‐Term Safety and Clinical Effects of Nilotinib in Parkinson's Disease	35
An Update on the Phenotype, Genotype and Neurobiology of ADCY5‐Related Disease	35
Classification of GBA1 Variants in Parkinson's Disease: The GBA1‐PD Browser	35
Locus Coeruleus Integrity from 7 T MRI Relates to Apathy and Cognition in Parkinsonian Disorders	34
Recent Advances in the Development of Stem‐Cell‐Derived Dopaminergic Neuronal Transplant Therapies for Parkinson's Disease	34
Isolated Cervical Dystonia: Diagnosis and Classification	34
Seven Solutions for Neuroprotection in Parkinson's Disease	34
Apathy Induced by Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease: A Meta‐Analysis	33
Locus Coeruleus Shows a Spatial Pattern of Structural Disintegration in Parkinson's Disease	33
Cognitive Behavioral Therapy for Anxiety in Parkinsonʼs Disease: A Randomized Controlled Trial	33
Dynamics of Top‐Down Control and Motor Networks in Parkinson's Disease	32
Functional Connectomics and Disease Progression in Drug‐Naïve Parkinson's Disease Patients	32
Neurofilament Light Chain Predicts Disease Severity and Progression in Multiple System Atrophy	32
Allogeneic Bone Marrow–Derived Mesenchymal Stem Cell Safety in Idiopathic Parkinson's Disease	32
Levodopa‐Carbidopa Intestinal Gel Reduces Dyskinesia in Parkinson's Disease in a Randomized Trial	32
Underrepresented Populations in Parkinson's Genetics Research: Current Landscape and Future Directions	32
Highlighting the Dystonic Phenotype Related to GNAO1	32
Treatment of *CSF1R*‐Related Leukoencephalopathy: Breaking New Ground	32
Magnetic Resonance‐Guided Focused Ultrasound Thalamotomy for Focal Hand Dystonia: A Pilot Study	31
Visual Dysfunction Predicts Cognitive Impairment and White Matter Degeneration in Parkinson's Disease	31
Clinical Diagnostic Accuracy of Parkinson's Disease: Where Do We Stand?	31
Resting‐State Functional Connectivity Predicts STN DBS Clinical Response	31
Uric Acid in Parkinson′s Disease: What Is the Connection?	31
Hypoxia Conditioning as a Promising Therapeutic Target in Parkinson's Disease?	31
Redefining Bradykinesia	30
Decoupling of Global Brain Activity and Cerebrospinal Fluid Flow in Parkinson's Disease Cognitive Decline	30
Asymmetric Dopamine Transporter Loss Affects Cognitive and Motor Progression in Parkinson's Disease	30
Monoacylglycerol Lipase Inhibition in Tourette Syndrome: A 12‐Week, Randomized, Controlled Study	30
Seed Amplification Assay to Diagnose Early Parkinson's and Predict Dopaminergic Deficit Progression	30
Brain Motor Network Changes in Parkinson's Disease: Evidence from Meta‐Analytic Modeling	30
Putaminal Recombinant Glucocerebrosidase Delivery with Magnetic Resonance–Guided Focused Ultrasound in Parkinson's Disease: A Phase I Study	30
The Logic and Pitfalls of Parkinson's Disease as “Brain‐First” Versus “Body‐First” Subtypes	30
Automated Categorization of Parkinsonian Syndromes Using Magnetic Resonance Imaging in a Clinical Setting	30
Neuroinflammation in the Cerebellum and Brainstem in Friedreich Ataxia: An [¹⁸F]‐FEMPA PET Study	30
α‐Synuclein Radiotracer Development and In Vivo Imaging: Recent Advancements and New Perspectives	29
Juvenile‐Onset Huntington Disease Pathophysiology and Neurodevelopment: A Review	29
Linking Parkinson's Disease and Melanoma: Interplay Between α‐Synuclein and Pmel17 Amyloid Formation	29
Abstracts of the MDS Virtual Congress 2021	29
Levodopa‐Induced Dyskinesia Are Mediated by Cortical Gamma Oscillations in Experimental Parkinsonism	29
Longitudinal Changes in Parkinson's Disease Symptoms with and Without Rapid Eye Movement Sleep Behavior Disorder: The Oxford Discovery Cohort Study	29
Cholinergic Basal Forebrain Volumes Predict Gait Decline in Parkinson's Disease	29
Plasma Glucosylsphingosine in GBA1 Mutation Carriers with and without Parkinson's Disease	29
Parkinson's Disease Modification Through Abl Kinase Inhibition: An Opportunity	29
A New MRI Measure to Early Differentiate Progressive Supranuclear Palsy From De Novo Parkinson's Disease in Clinical Practice: An International Study	28
Is Levodopa Response a Valid Indicator of Parkinson's Disease?	28
Euglycemia Indicates Favorable Motor Outcome in Parkinson's Disease	28
Innovating Parkinson's Care: A Randomized Controlled Trial of Telemedicine Depression Treatment	28
LRRK2 Inhibition by BIIB122 in Healthy Participants and Patients with Parkinson's Disease	28
Increased Menopausal Age Reduces the Risk of Parkinson's Disease: A Mendelian Randomization Approach	28
Relationship of Genotype, Phenotype, and Treatment in Dopa‐Responsive Dystonia: MDSGene Review	27
Increased Risk of Parkinson's Disease in Patients With Schizophrenia Spectrum Disorders	27
Concomitant Medication Usage with Levodopa‐Carbidopa Intestinal Gel: Results from the COSMOS Study	27
Genotype–Phenotype Relations for the Atypical Parkinsonism Genes: MDSGene Systematic Review	27
Functional Topography of the Human Subthalamic Nucleus: Relevance for Subthalamotomy in Parkinson's Disease	27
As Frequent as Polyglutamine Spinocerebellar Ataxias: SCA27B in a Large German Autosomal Dominant Ataxia Cohort	27
Evaluation of Strategies for Measuring Lysosomal Glucocerebrosidase Activity	27
Mild Chronic Colitis Triggers Parkinsonism in LRRK2 Mutant Mice Through Activating TNF‐α Pathway	27
Real‐Life Turning Movements Capture Subtle Longitudinal and Preataxic Changes in Cerebellar Ataxia	26
Diabetes, Glycated Hemoglobin (HbA1c), and Neuroaxonal Damage in Parkinson's Disease (MARK‐PD Study)	26
Profiling the Biochemical Signature of GBA‐Related Parkinson's Disease in Peripheral Blood Mononuclear Cells	26
The Emerging Role of Phosphodiesterases in Movement Disorders	26
A Chlorzoxazone‐Baclofen Combination Improves Cerebellar Impairment in Spinocerebellar Ataxia Type 1	26
FDG‐PET Patterns Predict Amyloid Deposition and Clinical Profile in Corticobasal Syndrome	26
Disruption of Brainstem Structural Connectivity in REM Sleep Behavior Disorder Using 7 Tesla Magnetic Resonance Imaging	26
Motor Cortical Network Excitability in Parkinson's Disease	26
Consensus Guidelines on Rodent Models of Restless Legs Syndrome	26
White Matter Hyperintensities, Dopamine Loss, and Motor Deficits in De Novo Parkinson's Disease	26
Efficacy of Caffeine in ADCY5‐Related Dyskinesia: A Retrospective Study	25
Motor Onset Topography and Progression in Parkinson's Disease: the Upper Limb Is First	25
Availability of Therapies and Services for Parkinson's Disease in Africa: A Continent‐Wide Survey	25
Perampanel Inhibits α‐Synuclein Transmission in Parkinson's Disease Models	24
Onset of Skin, Gut, and Genitourinary Prodromal Parkinson's Disease: A Study of 1.5 Million Veterans	24
A Machine‐Learning Derived Huntington's Disease Progression Model: Insights for Clinical Trial Design	24

Subcutaneous Levodopa Infusion for Parkinson's Disease: 1‐Year Data from the Open‐Label BeyoND Study	24
A Randomized, Placebo‐Controlled Crossover Study with Dipyridamole for Restless Legs Syndrome	24
Translating Evidence to Advanced Parkinson's Disease Patients: A Systematic Review and Meta‐Analysis	24
Striatal Dopamine Deficit and Motor Impairment in Idiopathic Normal Pressure Hydrocephalus	24
Re‐Analysis of the STEADY‐PD II Trial—Evidence for Slowing the Progression of Parkinson's Disease	24
Polyglutamine‐Expanded Ataxin‐3: A Target Engagement Marker for Spinocerebellar Ataxia Type 3 in Peripheral Blood	24
Dynamics of Nigral Iron Accumulation in Parkinson's Disease: From Diagnosis to Late Stage	24
A Double‐Blind, Randomized, Controlled Trial of Lovastatin in Early‐Stage Parkinson's Disease	24
Paving the Way Toward Meaningful Trials in Ataxias: An Ataxia Global Initiative Perspective	24
Neuroticism and Risk of Parkinson's Disease: A Meta‐Analysis	23
Development and Validation of Automated Magnetic Resonance Parkinsonism Index 2.0 to Distinguish Progressive Supranuclear Palsy‐Parkinsonism From Parkinson's Disease	23
Natural History and Phenotypic Spectrum of GAA‐FGF14 Sporadic Late‐Onset Cerebellar Ataxia (SCA27B)	23
Intrinsic Disruption of the M1 Cortical Network in a Mouse Model of Parkinson's Disease	23
Embracing Monogenic Parkinson's Disease: The MJFF Global Genetic PD Cohort	23
A Randomized, Double‐Blind, Controlled Phase II Study of Foliglurax in Parkinson's Disease	23
Comparison of Locus Coeruleus Pathology with Nigral and Forebrain Pathology in Parkinson's Disease	23
Phase 1/1b Studies of UCB0599, an Oral Inhibitor of α‐Synuclein Misfolding, Including a Randomized Study in Parkinson's Disease	23
Cerebrospinal α‐Synuclein Oligomers Reflect Disease Motor Severity in DeNoPa Longitudinal Cohort	23
Cerebello‐Cortical Control of Tremor Rhythm and Amplitude in Parkinson's Disease	23
Fine Particulate Matter Triggers α‐Synuclein Fibrillization and Parkinson‐like Neurodegeneration	23
Nicotinamide Riboside Improves Ataxia Scores and Immunoglobulin Levels in Ataxia Telangiectasia	23
StimFit—A Data‐Driven Algorithm for Automated Deep Brain Stimulation Programming	22
An MDS Evidence‐Based Review on Treatments for Huntington's Disease	22
Is Persistent Motor or Vocal Tic Disorder a Milder Form of Tourette Syndrome?	22
Longitudinal White Matter Damage Evolution in Parkinson's Disease	22
Pathological Validation of the MDS Criteria for the Diagnosis of Multiple System Atrophy	22
Apolipoprotein E Genotype Contributes to Motor Progression in Parkinson's Disease	22
A Randomized First‐in‐Human Study With UB‐312, a UBITh® α‐Synuclein Peptide Vaccine	22
Access and Attitudes Toward Palliative Care Among Movement Disorders Clinicians	22
Safety and Efficacy of Mevidalen in Lewy Body Dementia: A Phase 2, Randomized, Placebo‐Controlled Trial	22
Blood Markers of Inflammation, Neurodegeneration, and Cardiovascular Risk in Early Parkinson's Disease	22
A Gain‐of‐Function Variant in Dopamine D2 Receptor and Progressive Chorea and Dystonia Phenotype	22
Dairy Intake and Parkinson's Disease: A Mendelian Randomization Study	22
Multitarget Transcranial Electrical Stimulation for Freezing of Gait: A Randomized Controlled Trial	22
Glucocerebrosidase Activity is not Associated with Parkinson's Disease Risk or Severity	22
Gene Therapy for Polyglutamine Spinocerebellar Ataxias: Advances, Challenges, and Perspectives	22
TMEM151A Variants Cause Paroxysmal Kinesigenic Dyskinesia: A Large‐Sample Study	22
Bilateral Pallidotomy for Dystonia: A Systematic Review	22
Digital Gait Biomarkers Allow to Capture 1‐Year Longitudinal Change in Spinocerebellar Ataxia Type 3	22
Discussion of Research Priorities for Gait Disorders in Parkinson's Disease	22
Duodenal alpha‐Synuclein Pathology and Enteric Gliosis in Advanced Parkinson's Disease	21
Longitudinal Changes in Isolated Rapid Eye Movement Sleep Behavior Disorder‐Related Metabolic Pattern Expression	21
Brain Structural Signature of RFC1‐Related Disorder	21
A Statement of the MDS on Biological Definition, Staging, and Classification of Parkinson's Disease	21
Coding and Noncoding Variation in LRRK2 and Parkinson's Disease Risk	21
Cancer and Parkinson's Disease: Common Targets, Emerging Hopes	21
Risk Disclosure in Prodromal Parkinson's Disease	21
Brain and Systemic Inflammation in De Novo Parkinson's Disease	21
Randomized Trial of Botulinum Toxin Type A in Hereditary Spastic Paraplegia — The SPASTOX Trial	21
Saccade, Pupil, and Blink Responses in Rapid Eye Movement Sleep Behavior Disorder	20
Rehabilitating Cough Dysfunction in Parkinson's Disease: A Randomized Controlled Trial	20
Combining Skin α‐Synuclein Real‐Time Quaking‐Induced Conversion and Circulating Neurofilament Light Chain to Distinguish Multiple System Atrophy and Parkinson's Disease	20
Increased Risk of Parkinson's Disease in Women after Bilateral Oophorectomy	20
Pre‐ataxic Changes of Clinical Scales and Eye Movement in Machado–Joseph Disease: BIGPRO Study	20
High‐Frequency Oscillations in the Pallidum: A Pathophysiological Biomarker in Parkinson's Disease?	20
Fosmetpantotenate Randomized Controlled Trial in Pantothenate Kinase–Associated Neurodegeneration	20
Type 2 Diabetes and Parkinson's Disease: A Focused Review of Current Concepts	20
Is Pre‐Symptomatic Immunosuppression Protective in *CSF1R*‐Related Leukoencephalopathy?	20
Parkinson's Kinesia Paradoxa Is Not a Paradox	20
Epigenetic Clock Acceleration Is Linked to Age at Onset of Parkinson's Disease	20
Role of Lysosomal Gene Variants in Modulating GBA‐Associated Parkinson's Disease Risk	20
A Phase 2 Proof‐of‐Concept, Randomized, Placebo‐Controlled Trial of CX‐8998 in Essential Tremor	20
Functional Brain Dysconnectivity in Parkinson's Disease: A 5‐Year Longitudinal Study	20
Cerebrospinal FluidBiomarkers of Synaptic Dysfunction are Altered in Parkinson's Disease and Related Disorders	20
Connectivity Correlates of Anxiety Symptoms in Drug‐Naive Parkinson's Disease Patients	20
Depressive Symptoms and Suicidal Thoughts in Restless Legs Syndrome	20
Glia Imaging Differentiates Multiple System Atrophy from Parkinson's Disease: A Positron Emission Tomography Study with [¹¹C]PBR28 and Machine Learning Analysis	19
Small and Large Magnetic Resonance Imaging–Visible Perivascular Spaces in the Basal Ganglia of Parkinson's Disease Patients	19
Fluoxetine for the Symptomatic Treatment of Multiple System Atrophy: The MSA‐FLUO Trial	19
Corneal Confocal Microscopy Identifies Parkinson's Disease with More Rapid Motor Progression	19
Impaired Pre‐Motor Circuit Activity and Movement in a Drosophila Model of KCNMA1‐Linked Dyskinesia	19
On‐Demand Therapy for OFF Episodes in Parkinson's Disease	19
Genetic Modifiers of Age at Onset for Parkinson's Disease in Asians: A Genome‐Wide Association Study	19
Mild Parkinsonian Signs: A Systematic Review of Clinical, Imaging, and Pathological Associations	19
Deep Learning‐Based Neuromelanin MRI Changes of Isolated REM Sleep Behavior Disorder	19
CAG Repeat Expansion in THAP11 Is Associated with a Novel Spinocerebellar Ataxia	19
Proenkephalin Decreases in Cerebrospinal Fluid with Symptom Progression of Huntington's Disease	19
Elevated Urinary Rab10 Phosphorylation in Idiopathic Parkinson Disease	18
Exposure to Phosphoglycerate Kinase 1 Activators and Incidence of Parkinson's Disease	18
Accelerated Transcranial Ultrasound Neuromodulation in Parkinson's Disease: A Pilot Study	18
Non‐Motor Fluctuations in Parkinson's Disease: Validation of the Non‐Motor Fluctuation Assessment Questionnaire	18
Serum Neurofilament Light Chain as a Biomarker of Brain Injury in Wilson's Disease: Clinical and Neuroradiological Correlations	18
Defective Somatosensory Inhibition and Plasticity Are Not Required to Develop Dystonia	18
The Signature of Primary Writing Tremor Is Dystonic	18
Cerebral Microbleeds in Fragile X–Associated Tremor/Ataxia Syndrome	18
Transcutaneous Auricular Vagus Stimulation Improves Gait and Reaction Time in Parkinson's Disease	18
Increased Climbing Fiber Lateral Crossings on Purkinje Cell Dendrites in the Cerebellar Hemisphere in Essential Tremor	18
Astrocytic Changes in Mitochondrial Oxidative Phosphorylation Protein Levels in Parkinson's Disease	18
The Endotoxin Hypothesis of Parkinson's Disease	18
Cytokines and Gaucher Biomarkers in Glucocerebrosidase Carriers with and Without Parkinson Disease	18
Variability of Movement Disorders: The Influence of Sensation, Action, Cognition, and Emotions	17
Parkinsonism as a Sequela of SARS‐CoV‐2 Infection: Pure Hypoxic Injury or Additional COVID‐19‐Related Response?	17
Dual Task Turning in Place: A Reliable, Valid, and Responsive Outcome Measure of Freezing of Gait	17
Defining the Riddle in Order to Solve It: There Is More Than One “Parkinson's Disease”	17
The Chinese Parkinson's Disease Registry (CPDR): Study Design and Baseline Patient Characteristics	17